Blocking cytokines with genes

Christopher H Evans, S. C. Ghivizzani, P. D. Robbins

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The pathophysiology of rheumatoid arthritis (RA) is primarily driven by proinflammatory cytokines such as interleukin-1 (IL-1) and tumor necrosis factor a. Several biological agents have been identified that effectively block the activity of these cellular messengers, and administration of these agents to animal models of RA and human patients has been found to have therapeutic benefit. The application of gene therapy for the treatment of RA and other articular diseases is being explored to overcome current limitations with delivery of therapeutics to joint tissues. To date, laboratory research has focused on two main areas: (1) evaluation of gene delivery approaches and (2) identification of therapeutic gene products. Considerable progress has been reported with the use of local gene delivery to synovial cells by both in vivo and ex vivo methods and by systemic administration of gene delivery vectors via the circulation. Gene products that have therapeutic efficacy in animal models of RA include: IL-1 receptor antagonist, soluble IL-1 receptor I, soluble tumor necrosis factor receptor II, viral IL-10, and transforming growth factor β, among others. The success of these laboratory studies has led to the implementation of a Phase I clinical trial to asses the safety and feasibility of using gene therapy in the treatment of RA.

Original languageEnglish (US)
Pages (from-to)55-61
Number of pages7
JournalJournal of Leukocyte Biology
Volume64
Issue number1
StatePublished - Jul 1998
Externally publishedYes

Fingerprint

Rheumatoid Arthritis
Cytokines
Genes
Interleukin-1 Receptors
Genetic Therapy
Therapeutics
Animal Models
Joints
Clinical Trials, Phase I
Equidae
Tumor Necrosis Factor Receptors
Biological Factors
Transforming Growth Factors
Interleukin-1
Interleukin-10
Tumor Necrosis Factor-alpha
Safety
Research

Keywords

  • Gene therapy
  • Inflammation

ASJC Scopus subject areas

  • Cell Biology

Cite this

Evans, C. H., Ghivizzani, S. C., & Robbins, P. D. (1998). Blocking cytokines with genes. Journal of Leukocyte Biology, 64(1), 55-61.

Blocking cytokines with genes. / Evans, Christopher H; Ghivizzani, S. C.; Robbins, P. D.

In: Journal of Leukocyte Biology, Vol. 64, No. 1, 07.1998, p. 55-61.

Research output: Contribution to journalArticle

Evans, CH, Ghivizzani, SC & Robbins, PD 1998, 'Blocking cytokines with genes', Journal of Leukocyte Biology, vol. 64, no. 1, pp. 55-61.
Evans CH, Ghivizzani SC, Robbins PD. Blocking cytokines with genes. Journal of Leukocyte Biology. 1998 Jul;64(1):55-61.
Evans, Christopher H ; Ghivizzani, S. C. ; Robbins, P. D. / Blocking cytokines with genes. In: Journal of Leukocyte Biology. 1998 ; Vol. 64, No. 1. pp. 55-61.
@article{11c2ce19c678410c968ae8af912de8af,
title = "Blocking cytokines with genes",
abstract = "The pathophysiology of rheumatoid arthritis (RA) is primarily driven by proinflammatory cytokines such as interleukin-1 (IL-1) and tumor necrosis factor a. Several biological agents have been identified that effectively block the activity of these cellular messengers, and administration of these agents to animal models of RA and human patients has been found to have therapeutic benefit. The application of gene therapy for the treatment of RA and other articular diseases is being explored to overcome current limitations with delivery of therapeutics to joint tissues. To date, laboratory research has focused on two main areas: (1) evaluation of gene delivery approaches and (2) identification of therapeutic gene products. Considerable progress has been reported with the use of local gene delivery to synovial cells by both in vivo and ex vivo methods and by systemic administration of gene delivery vectors via the circulation. Gene products that have therapeutic efficacy in animal models of RA include: IL-1 receptor antagonist, soluble IL-1 receptor I, soluble tumor necrosis factor receptor II, viral IL-10, and transforming growth factor β, among others. The success of these laboratory studies has led to the implementation of a Phase I clinical trial to asses the safety and feasibility of using gene therapy in the treatment of RA.",
keywords = "Gene therapy, Inflammation",
author = "Evans, {Christopher H} and Ghivizzani, {S. C.} and Robbins, {P. D.}",
year = "1998",
month = "7",
language = "English (US)",
volume = "64",
pages = "55--61",
journal = "Journal of Leukocyte Biology",
issn = "0741-5400",
publisher = "FASEB",
number = "1",

}

TY - JOUR

T1 - Blocking cytokines with genes

AU - Evans, Christopher H

AU - Ghivizzani, S. C.

AU - Robbins, P. D.

PY - 1998/7

Y1 - 1998/7

N2 - The pathophysiology of rheumatoid arthritis (RA) is primarily driven by proinflammatory cytokines such as interleukin-1 (IL-1) and tumor necrosis factor a. Several biological agents have been identified that effectively block the activity of these cellular messengers, and administration of these agents to animal models of RA and human patients has been found to have therapeutic benefit. The application of gene therapy for the treatment of RA and other articular diseases is being explored to overcome current limitations with delivery of therapeutics to joint tissues. To date, laboratory research has focused on two main areas: (1) evaluation of gene delivery approaches and (2) identification of therapeutic gene products. Considerable progress has been reported with the use of local gene delivery to synovial cells by both in vivo and ex vivo methods and by systemic administration of gene delivery vectors via the circulation. Gene products that have therapeutic efficacy in animal models of RA include: IL-1 receptor antagonist, soluble IL-1 receptor I, soluble tumor necrosis factor receptor II, viral IL-10, and transforming growth factor β, among others. The success of these laboratory studies has led to the implementation of a Phase I clinical trial to asses the safety and feasibility of using gene therapy in the treatment of RA.

AB - The pathophysiology of rheumatoid arthritis (RA) is primarily driven by proinflammatory cytokines such as interleukin-1 (IL-1) and tumor necrosis factor a. Several biological agents have been identified that effectively block the activity of these cellular messengers, and administration of these agents to animal models of RA and human patients has been found to have therapeutic benefit. The application of gene therapy for the treatment of RA and other articular diseases is being explored to overcome current limitations with delivery of therapeutics to joint tissues. To date, laboratory research has focused on two main areas: (1) evaluation of gene delivery approaches and (2) identification of therapeutic gene products. Considerable progress has been reported with the use of local gene delivery to synovial cells by both in vivo and ex vivo methods and by systemic administration of gene delivery vectors via the circulation. Gene products that have therapeutic efficacy in animal models of RA include: IL-1 receptor antagonist, soluble IL-1 receptor I, soluble tumor necrosis factor receptor II, viral IL-10, and transforming growth factor β, among others. The success of these laboratory studies has led to the implementation of a Phase I clinical trial to asses the safety and feasibility of using gene therapy in the treatment of RA.

KW - Gene therapy

KW - Inflammation

UR - http://www.scopus.com/inward/record.url?scp=0031777629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031777629&partnerID=8YFLogxK

M3 - Article

C2 - 9665275

AN - SCOPUS:0031777629

VL - 64

SP - 55

EP - 61

JO - Journal of Leukocyte Biology

JF - Journal of Leukocyte Biology

SN - 0741-5400

IS - 1

ER -